OVERSEA CHINESE BANKING Corp Ltd Makes New $696,000 Investment in Humana Inc. (NYSE:HUM)

OVERSEA CHINESE BANKING Corp Ltd purchased a new position in Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,575 shares of the insurance provider's stock, valued at approximately $696,000.

A number of other large investors also recently added to or reduced their stakes in the stock. Dodge & Cox raised its position in shares of Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares during the last quarter. Norges Bank purchased a new position in shares of Humana in the fourth quarter valued at approximately $416,202,000. Boston Partners boosted its stake in shares of Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock worth $279,236,000 after acquiring an additional 893,637 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Humana by 40,881.1% in the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock worth $2,066,790,000 after acquiring an additional 779,193 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HUM. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Thursday, May 1st. Oppenheimer lifted their price target on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research note on Thursday, May 1st. Mizuho raised their target price on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a research note on Thursday, May 1st. Finally, Wall Street Zen lowered shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $279.81.

Humana Trading Down 2.3%

Humana stock traded down $5.19 during trading on Friday, hitting $218.36. The company had a trading volume of 2,008,472 shares, compared to its average volume of 1,687,489. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $406.09. The company's 50 day simple moving average is $235.46 and its 200-day simple moving average is $257.46. The stock has a market cap of $26.35 billion, a price-to-earnings ratio of 15.44, a price-to-earnings-growth ratio of 1.55 and a beta of 0.44. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. During the same period last year, the business posted $7.23 earnings per share. The company's quarterly revenue was up 8.4% on a year-over-year basis. As a group, analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.